e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
REGENXBIO Inc. - Common Stock
(NQ:
RGNX
)
7.620
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about REGENXBIO Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Where Regenxbio Stands With Analysts
December 11, 2024
Via
Benzinga
Workday, Apollo Global To Join S&P 500 Index In Quarterly Balance
December 06, 2024
They'll join the index before the open on Dec. 23 as part of a quarterly rebalance.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
What's Going On With REGENXBIO Shares Monday?
November 18, 2024
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
Via
Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
November 18, 2024
Via
Benzinga
5 Analysts Have This To Say About Regenxbio
November 15, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
October 10, 2024
Via
Benzinga
Assessing Regenxbio: Insights From 5 Financial Analysts
September 04, 2024
Via
Benzinga
Where Regenxbio Stands With Analysts
August 05, 2024
Via
Benzinga
Assessing Regenxbio: Insights From 4 Financial Analysts
June 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 06, 2024
Via
Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
Evaluating Regenxbio: Insights From 9 Financial Analysts
May 15, 2024
Via
Benzinga
Where Regenxbio Stands With Analysts
April 12, 2024
Via
Benzinga
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
March 06, 2024
Via
Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Why Is Clearside Biomedical Stock Gaining Today?
June 25, 2024
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS...
Via
Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
June 21, 2024
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.
Via
Benzinga
Exposures
Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
June 20, 2024
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.
Via
Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
June 13, 2024
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.
Via
Investor's Business Daily
Exposures
Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Via
Benzinga
RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
March 25, 2024
Via
Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
March 13, 2024
The threat is still emerging, but it could be significant.
Via
The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
March 08, 2024
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.
Via
Benzinga
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
March 05, 2024
Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 05, 2024
Via
Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 01, 2024
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.
Via
Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
wpDiscuz
Insert